Joaquin Duato, CEO and Chairman of Johnson & Johnson (JNJ), has demonstrated a clear selling bias in his recent insider transactions, with $72.1 million in total sales outweighing $24.7 million in purchases across 26 reported trades. His most significant disposals occurred on January 26, 2026, when he sold $10.8 million and $11.3 million worth of JNJ shares, following an earlier $22.5 million sale on August 22, 2025. These open-market sales contrast with his acquisition activity, which primarily involved smaller transactions such as a $390,006 purchase on February 15, 2026, and a $477,162 acquisition the same day.
The pattern shows Duato consistently reducing his JNJ position since 2024, with no recent buys offsetting his sales. While he acquired shares through derivative transactions—including a $15.5 million purchase on February 9, 2024—his disposals have been larger and more frequent. Notably, his February 2026 transactions included multiple small purchases alongside substantial sales, reinforcing a net divestment trend. All activity remains confined to JNJ, with no trades in other securities reported. The data reflects a sustained reduction in exposure to his company’s stock over the past two years.
AI-assisted summary